Trengestone
Trengestone, sold under the brand names Reteroid, Retroid, and Retrone, is a progestin medication which was formerly used to treat menstrual disorders but is now no longer marketed. It is taken by mouth.
Clinical data | |
---|---|
Trade names | Reteroid, Retroid, Retrone |
Other names | Ro 4-8347; Triengestone; 1,6-Didehydro-6-chlororetroprogesterone; 6-Chloro-9β-10α-pregna-1,4,6-triene-3,20-dione |
Routes of administration | By mouth |
Drug class | Progestogen; Progestin |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | ≥41–46% (based on urinary excretion) |
Metabolism | Liver |
Metabolites | • 20α-Dihydrotrengestone |
Elimination half-life | • Trengestone: very short • 20α-DHTG: 8–14 hours |
Excretion | Urine: 41–46% Feces: 30% (unchanged) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
ECHA InfoCard | 100.023.617 |
Chemical and physical data | |
Formula | C21H25ClO2 |
Molar mass | 344.88 g·mol−1 |
3D model (JSmol) | |
| |
|
Side effects of trengestone include headache, fatigue, and breast tenderness among others. Trengestone is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. It is not androgenic or estrogenic.
Trengestone was introduced for medical use in 1974. It is no longer available.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.